Avrobio

Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More

If you’re into congressional spectacles, stay tuned later this month.

A group of top biopharma executives—the full roster isn’t known yet—will testify at a Feb. 26 hearing before the Senate Committee on Finance to defend their drug pricing practices. No executives showed up for the previous hearing, but reports indicate industry has changed its stance under pressure: Both chambers of Congress have kicked up their efforts to battle drug pricing of late, and the Trump administration just announced a plan to overhaul the secretive rebate deals between drug companies and pharmacy benefit managers.

Will the hearing lead to meaningful change… Read more »

UNDERWRITERS AND PARTNERS

          

          

            
https://xconomy.com/national/2019/02/08/bio-roundup-new-crispr-feud-a-ny-splash-pharma-vs-congress-more/

Advertisements
READ  Lexicon pain drug advances after clearing early clinical test

Leave a Reply